| Repurposed antiviral drugs for COVID-19—interim WHO SOLIDARITY trial results WHO Solidarity Trial Consortium New England journal of medicine 384 (6), 497-511, 2021 | 2983 | 2021 |
| HLA-B*5701 screening for hypersensitivity to abacavir S Mallal, E Phillips, G Carosi, PS Team N Engl J Med 358 (6), 568-79, 2008 | 2348 | 2008 |
| Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy AJ Rodger, V Cambiano, T Bruun, P Vernazza, S Collins, J Van Lunzen, ... Jama 316 (2), 171-181, 2016 | 1990 | 2016 |
| Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of … AJ Rodger, V Cambiano, T Bruun, P Vernazza, S Collins, O Degen, ... The Lancet 393 (10189), 2428-2438, 2019 | 1385 | 2019 |
| Dolutegravir plus abacavir–lamivudine for the treatment of HIV-1 infection SL Walmsley, A Antela, N Clumeck, D Duiculescu, A Eberhard, ... New England Journal of Medicine 369 (19), 1807-1818, 2013 | 1154 | 2013 |
| Maraviroc for previously treated patients with R5 HIV-1 infection RM Gulick, J Lalezari, J Goodrich, N Clumeck, E DeJesus, A Horban, ... New England Journal of Medicine 359 (14), 1429-1441, 2008 | 965 | 2008 |
| The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. HIVC Collaboration AIDS 24 (1), 123-37., 2010 | 610 | 2010 |
| Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial DA Margolis, J Gonzalez-Garcia, HJ Stellbrink, JJ Eron, Y Yazdanpanah, ... The Lancet 390 (10101), 1499-1510, 2017 | 601 | 2017 |
| Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19 A Meta-analysis WHOREA COVID JAMA-Journal of the American Medical Association 326 (6), 499-518, 2021 | 578* | 2021 |
| Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques. OBKL Said MA, Johnson HL, Nonyane BA, Deloria-Knoll M PLoS One 8 (4), e60273, 2013 | 554 | 2013 |
| Antifungal drug resistance to azoles and polyenes MM Canuto, FG Rodero The Lancet infectious diseases 2 (9), 550-563, 2002 | 444 | 2002 |
| Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection G Fätkenheuer, M Nelson, A Lazzarin, I Konourina, AIM Hoepelman, ... New England Journal of Medicine 359 (14), 1442-1455, 2008 | 437 | 2008 |
| Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain J Berenguer, P Ryan, J Rodriguez-Bano, I Jarrin, J Carratala, J Pachon, ... Clinical Microbiology and Infection 26 (11), 1525-1536, 2020 | 409 | 2020 |
| Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses H Pan, R Peto, AMH Restrepo, MP Preziosi, V Sathiyamoorthy, QA Karim, ... The Lancet 399 (10339), 1941-1953, 2022 | 376 | 2022 |
| When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study. HIVC Collaboration Ann Intern Med. 154 (8), 509-15, 2011 | 362 | 2011 |
| Evaluation of the Immunochromatographic Binax NOW Assay for Detection of Streptococcus pneumoniae Urinary Antigen in a Prospective Study of Community … F Gutiérrez, M Mar, JC Rodríguez, A Ayelo, B Soldán, L Cebrián, C Mirete, ... Clinical Infectious Diseases 36 (3), 286-292, 2003 | 357 | 2003 |
| Usefulness of procalcitonin levels in community-acquired pneumonia according to the patients outcome research team pneumonia severity index M Masiá, F Gutiérrez, C Shum, S Padilla, JC Navarro, E Flores, ... Chest 128 (4), 2223-2229, 2005 | 302 | 2005 |
| The influence of age and gender on the population-based incidence of community-acquired pneumonia caused by different microbial pathogens F Gutiérrez, M Masiá, C Mirete, B Soldán, JC Rodríguez, S Padilla, ... Journal of infection 53 (3), 166-174, 2006 | 298 | 2006 |
| Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring F Gutiérrez, A Navarro, S Padilla, R Antón, M Masiá, J Borrás, ... Clinical infectious diseases 41 (11), 1648-1653, 2005 | 296 | 2005 |
| Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study E Martinez, M Larrousse, JM Llibre, F Gutierrez, M Saumoy, A Antela, ... Aids 24 (11), 1697-1707, 2010 | 249 | 2010 |
MARIA DEL MAR MASIAInfectious Diseases, Professor of MedicineVerified email at umh.es
